VESIcare

ApprovedSmall molecule

Astellas

VESIcare is one of 53 small molecule programs targeting Multiple Sclerosis. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Multiple SclerosisActive, not recruiting

Overactive BladderActive, not recruiting

Multiple SclerosisApproved

Active, not recruiting

Overactive BladderPhase 3

Active, not recruiting

Competition

Competitive Landscape

560 competitors in Multiple Sclerosis

#DrugCompanyPhaseTrials

VESIcare

Astellas

Approved

1 2

Betaseron

Bayer

Preclinical

16 3

Kesimpta

Novartis

Preclinical

15 4

Tysabri

Biogen

Preclinical

14 5

Avonex

EMD Serono

Preclinical

22 6

Campath

GGenzyme, a Sanofi Company

Preclinical

12 7

Zinbryta

Roche

Preclinical

2 8

Novantrone

Pfizer

Preclinical

—9

Circadin

NNeurim Pharmaceuticals Ltd.

Preclinical

3 10

Proair HFA

GGlaxo Dba Glaxosmithkline

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Overactive Bladder2 trials

A Multicenter VESIcare® Efficacy and Safety Study for the Treatment of Urgency Associated With Overactive Bladder (OAB)

Completed· Astellas logo

Astellas·Phase 3·NCT00454896·739 enrolled

Behavioral Modification and Vesicare Versus Vesicare Alone for Urge Incontinence in Patients With Overactive Bladder

Terminated·LLahey Clinic·Phase 3·NCT00821184·12 enrolled

Prostatectomy2 trials

Study to Determine Effects of Vesicare on Return to Continence Post- Radical Prostatectomy

Terminated·UUniversity of California, Irvine·N/A·NCT00581061·13 enrolled

Study to Determine Effects of Vesicare on Return to Continence Post - Radical Prostatectomy (Part II)

Completed·UUniversity of California, Irvine·N/A·NCT01215721·40 enrolled

Multiple Sclerosis1 trial

Botulinum Toxin a Vs Anticholinergic Treatment of Neurogenic Overactive Bladder in Patients with Multiple Sclerosis

Terminated·BBrigitte Schürch·Phase 4·NCT04819360·1 enrolled

CAR1 trial

Post Marketing Survey of Vesicare in Japan

Completed· Astellas logo

Astellas··NCT01489709·1,160 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for VESIcare. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — VESIcare compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for VESIcare. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Astellas company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: Astellas

VESIcare

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Overactive Bladder2 trials

Prostatectomy2 trials

Multiple Sclerosis1 trial

CAR1 trial

References

Drug Info

Quick Facts

Related News